This project has received funding from the European Commission’s Horizon 2020 research and innovation programme under grant agreement No 825162.

€ 9.640.775

January 2019 – December 2023 (five years)

Utrecht University


• Copenhagen University
• Oulun Yliopisto
• University of York
• Medical University Sofia
• University of Bern
• Polytechnic University of Madrid
• European Organisation for Research and Treatment of Cancer
• Tandvards-Och Lakemedelsformansverket
• Zorginstituut Nederland
• National Institute for Health and Care Excellence
• Syreon Research InstituteSynapse Research Management Partners
• Maastricht University

‘Why it matters’

With the development of new medicines, the treatment of many cancers is advancing. However, the cost of new cancer treatments is often very high and health systems face a difficult decision about where to invest limited funds. This decision is made through a process called Health Technology Assessment (HTA). HTx is to create a framework for the Next Generation HTA to support patient-centered, societally oriented, real-time decision-making on access to and reimbursement for health technologies throughout Europe.

HTx will facilitate the development of methodologies to deliver more customized information on the effectiveness and cost-effectiveness of complex and personalised combinations of health technologies. HTx will also provide methods to support personalised treatment advice that will be shared with patients and their physicians. Finally, HTx will, in close collaboration with the European Network for HTA (EUnetHTA) and its stakeholders, pilot the implementation of these methods in Europe.

“Health Technology Assessment plays a crucial role in ensuring the sustainability of national healthcare systems across Europe. The concept of value should go beyond clinical data, including patient-reported outcome measures, such as quality of life, but also look at the wider economic and societal impact medicines have and their contribution to the sustainability of national healthcare systems. We must avoid silos in budgets and in the assessment of value of medicines that is so common in our healthcare systems today. Without HTA – we can’t assess value across the board in all relevant domains and we need a unified, mandatory framework to achieve this in Europe” – Jacqueline Daly, ECPC Board Member.

‘What ECPC does’

When the HTx project will hold a stakeholders’ events, a fellowship programme will allow patients’ advocates to attend the event and to engage directly with the project team. When HTx will present its findings to other conferences of interest, the same fellowship programme will help dedicated patient advocates attend the conference to listen to the presentations and to interact with the audience.

ECPC Director Antonella Cardone sits on the project’s Stakeholder Advisory Board, the HTx Forum. She ensures the project activities are in line with the needs of cancer patients by actively participating in discussions and providing feedback and input on research activities, use cases and outputs.

EU flag logo

This project is funded by the European Union